Stock Analysis

Insiders Own Up To 34% Of These 3 Growth Stocks On KRX

Published

The South Korean stock market has seen a downward trend over the past three sessions, with the KOSPI index slipping more than 4 percent and currently resting just above the 2,575-point mark. Amid this volatility, investors are increasingly looking for growth companies where insiders have significant ownership stakes, as these can often signal strong confidence in the company's future prospects.

Top 10 Growth Companies With High Insider Ownership In South Korea

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.5%35.6%
Seojin SystemLtd (KOSDAQ:A178320)30.6%52.1%
Bioneer (KOSDAQ:A064550)17.5%97.6%
ALTEOGEN (KOSDAQ:A196170)26.6%99.5%
Oscotec (KOSDAQ:A039200)26.3%122%
Vuno (KOSDAQ:A338220)19.5%110.9%
HANA Micron (KOSDAQ:A067310)21.3%106.2%
INTEKPLUS (KOSDAQ:A064290)16.3%96.7%
UTI (KOSDAQ:A179900)33.1%134.6%
Techwing (KOSDAQ:A089030)18.7%83.6%

Click here to see the full list of 87 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Park Systems (KOSDAQ:A140860)

Simply Wall St Growth Rating: ★★★★★★

Overview: Park Systems Corp. develops, manufactures, and sells atomic force microscopy (AFM) systems worldwide and has a market cap of ₩1.17 trillion.

Operations: Park Systems Corp. generates revenue primarily from the development, manufacturing, and sales of atomic force microscopy (AFM) systems on a global scale.

Insider Ownership: 33%

Park Systems, a South Korean firm specializing in atomic force microscopy (AFM), recently launched the Park FX200, enhancing its large-sample AFM technology. The company boasts high insider ownership and is expected to see significant revenue growth at 23.6% annually, outpacing the market. Earnings are forecasted to grow by 35.66% per year. Trading below fair value and with analysts predicting a 31.1% price rise, it remains an attractive growth prospect despite no recent substantial insider trading activity.

KOSDAQ:A140860 Earnings and Revenue Growth as at Sep 2024

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc. is a biotech research company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.32 trillion.

Operations: The company's revenue segment is primarily derived from Biotechnology (Startups), amounting to ₩32.95 billion.

Insider Ownership: 30.6%

ABL Bio, a South Korean biotech firm, is forecast to grow its revenue by 24.7% annually, outpacing the market's 10.6%. Analysts expect the company to become profitable within three years and predict a 40.7% rise in stock price. Despite high volatility in share price recently, ABL Bio completed a significant private placement worth ₩139.99 billion (approximately US$105 million) in July 2024, indicating strong investor confidence and substantial insider ownership support for future growth initiatives.

KOSDAQ:A298380 Earnings and Revenue Growth as at Sep 2024

APR (KOSE:A278470)

Simply Wall St Growth Rating: ★★★★★☆

Overview: APR Co., Ltd manufactures and sells cosmetic products for men and women, with a market cap of ₩2.17 billion.

Operations: The company's revenue segments include ₩614.77 million from cosmetics and ₩64.46 million from apparel fashion.

Insider Ownership: 34.4%

APR Co., Ltd. is trading at 44.6% below its estimated fair value, with earnings expected to grow significantly over the next three years. Despite high share price volatility recently, analysts predict a 43.6% rise in stock price and forecast revenue growth of 22.2% per year, outpacing the South Korean market's 10.6%. The company announced a KRW 60 billion share repurchase program to stabilize stock prices and enhance shareholder value, reflecting strong insider confidence in future growth prospects.

KOSE:A278470 Ownership Breakdown as at Sep 2024

Seize The Opportunity

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com